MedTrace Logo

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

NCT00405067 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-03-04

Study results available
· View outcomes & findings →

Summary

The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.

Conditions

Interventions

DRUG

BMS-201038 (AEGR-733)

DRUG

Ezetimibe

Sponsors & Collaborators

  • Aegerion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Davidson, MD · Radiant Research

  • Jackson Downey, MD · Jacksonville Center For Clinical Research

  • Paul Grena, MD · Cardiology Consultants of Philadelphia

  • Barry Lubin, MD · Hampton Roads Center for Clinical Research

  • James McKenney, Pharm D · National Clinical Research

  • Eli Roth, MD · Sterling Research Group, LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405067 on ClinicalTrials.gov